Genzyme Convenes 4th Annual Gaucher Leadership Forum in Munich

Forum provides platform to discuss current and future management of Gaucher disease

Media Contact:

[email protected]

, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the fourth annual Gaucher Leadership Forum (GLF) will take place on September 21 and 22 in Munich, Germany. The GLF is a scientific meeting sponsored by Genzyme that brings together more than 200 participants from around the world, including physicians, academics, researchers and patient organization representatives to discuss current care for patients with Gaucher disease and the direction of future disease management. This year’s GLF is chaired by Dr. Pram Mistry, Professor of Pediatrics and Internal Medicine, Director of the National Gaucher Disease Treatment Center and Chief of Pediatric Gastroenterology/Hepatology at Yale University School of Medicine.

“The GLF is an opportunity for creative exchange of new insights and for collaboration among members of the global Gaucher community to enhance the care of those living with Gaucher disease, with an emphasis on personalized medicine,” said Dr. Mistry. “This forum will bring into sharp focus unmet needs in Gaucher disease and help define our vision for the future.”

In addition to Dr. Mistry’s role as Chair of the forum, a Scientific Steering Committee of five international experts collaborated on the content of the meeting. The plenary presentations will highlight unmet needs in current Gaucher disease management and working groups will assess the current state of knowledge on key topics to develop a roadmap for future investigations.

Genzyme’s President and Chief Executive Officer, David Meeker, M.D., will provide opening remarks at the meeting. “The GLF has evolved from a local, European meeting to a global one in scope, but still driven by a simple objective – to collaborate across our community with the common goal of transforming the lives of patients living with Gaucher,” said Dr. Meeker. “The momentum of ongoing research, combined with the opportunities to improve the care of patients, make this a critical moment for thought leaders to come together.”

Among the presenters at this year’s GLF are some of the previous winners of the Gaucher Generation program. Since 2008, this Genzyme program has provided annual research awards to researchers throughout the world to stimulate and support the advancement of medical knowledge in Gaucher disease. An independent committee of international Gaucher disease experts reviews the submitted research proposals to select the most meritorious applications. Later this year, Genzyme will award two “New Investigator Awards,” with each recipient receiving an award of up to $100,000 provided over two years, as well as one “Established Investigator Award,” with an award of up to $150,000 also provided over two years.

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at .

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).